uk centre for medical research and innovation

Please enable JavaScript in your web browser to get the best experience.

We use cookies to track usage and preferences.

Primary navigation

• PhD students
• Exhibitions
• Translation
• Work experience

Discoveries to change lives

We're one of Europe's biggest labs and home to more than 1,500 scientists working to understand health, disease and how life works.

WE NEED THE EXHBITION TITLE HERE

Images of science.

Sixteen scientific images have been chosen to represent Crick research in a travelling international exhibition.

Latest news

Crick annual animal research numbers published, crick skylab opens as msd commence new research programmes, fabian fröhlich awarded erc starting grant, £2m awarded to study heart development in zebrafish, sign up for our newsletters.

Join our mailing lists to receive updates about our latest research and to hear about our free public events and exhibitions.  If you would like to find out more about how we manage your personal information please see our privacy policy .

The Francis Crick Institute is a unique partnership between

MRC Impact Showcase

How the people and projects we invest in at the Medical Research Council (MRC) are making an impact on our lives and the world we live in.

Our mission at the Medical Research Council (MRC), part of UK Research and Innovation, is to improve human health through world-class medical research. To achieve this, we invest public money into some of the best medical rese arch in the world across every area of health. Our work has led to some of medicine’s biggest breakthroughs – from deciphering DNA’s structure to inventing the MRI scanner and developing the first COVID-19 vaccine. Our scientists have transformed modern medicine, and in turn have been recognised by 32 Nobel Prizes.

The impacts of our work are broad and diverse – benefiting the economy, society, culture, public policy and services, health, the environment, and quality of life for people in the UK and around the world. They are made possible not just through funding science, but also through targeted investment supporting entrepreneurial activity and supporting enterprise. MRC has built up emerging areas and funded world-class ideas, working with stakeholders across all sectors and partners across the world, guided by our vision to accelerate improvements in human health and economic prosperity.

The case studies below showcase just some of the non-academic impacts arising from MRC funding, with examples from higher education institutes (HEIs) and MRC-supported institutes and major investments.

Credit: Dr Daniyal Jafree and Professor David Long, Kidney Development and Disease Group, UCL Great Ormond Street Institute of Child Health

MRC supporting jobs and boosting the UK economy

First gene therapies for haemophilia, and creation of spin-out Freeline Therapeutics

• UCL developed single-dose gene therapy that restores blood-clotting and can be delivered at 1% of the cost of conventional treatment – changing the lives of thousands with haemophilia
• The inherited disorder causes internal bleeding and significantly affects 800,000 affected men and boys worldwide
• Therapies have treated over 300 patients in clinical trials to date, and a spin-out company, Freeline Therapeutics, was launched in 2015 to develop the approach
• MRC funding has supported the underpinning haemophilia research for over 60 years

New cancer therapies insight leads to spin-out companies worth £54m and 326 new jobs

• Research into how cancer cells interact with the immune system has led to new avenues for developing treatments
• Researchers at the Francis Crick Institute – a partnership between MRC, Cancer Research UK and Wellcome – have identified several unique cellular processes involved in driving cancer growth, providing opportunities to develop targeted therapies aimed at disrupting them
• The research has led to several spin-out companies, collectively valued at £54.4m and employing 326 people, with several therapeutic candidates in phase I/II trials for melanoma, solid cancers and leukaemia

Creating the world’s largest retinal gene therapy company

• Gene-therapy research into inherited diseases that cause blindness led to new treatments and the formation of a successful spin-out company
• MRC-funded research at Imperial College London and the University of Oxford pioneered the first clinical trials of gene therapy for the diseases choroideremia and X-linked retinal pigmentosa, which demonstrated significant improvement in vision for some of the patients treated
• Spin-out company Nightstar was created with the novel treatment as its lead programme. Licensing of subsequent research extended the approach to other kinds of retinal pigmentosa, and created the world’s largest retinal gene therapy company

MRC tackling the impact of COVID-19

Global adoption of effective COVID-19 treatments saves lives

• RECOVERY trial (Randomised Evaluation of COVID-19 Therapy) – world’s largest clinical trial into treatments for COVID-19, more than 48,000 participants across 185 sites
• Results found dexamethasone, a cheap, readily available steroid, reduces death rates among seriously unwell patients
• Findings immediately transformed global clinical guidelines and practice
• MRC funding directly supported RECOVERY trial through the COVID-19 Rapid Response Initiative in 2020 with the National Institute of Health Research
• The initiative saved an estimated 650,000 lives by the end of 2020
•   Find out more about the RECOVERY trial

Oxford-AstraZeneca Covid-19 vaccine contributed to 6.3m lives saved

• Oxford-AstraZeneca COVID-19 vaccine contributed to saving 6.3 million lives around the world in the first year of rollout
• More than 11,000 trial participants showed 70% reduced risk of COVID-19 and 100% reduction in risk of hospitalisation or death
• MRC funding supported vaccine’s development – success underpinned by decades of MRC funded research that supported the development of ChAdOx1 platform – an adenoviral vector for vaccines to induce and boost cellular immunity
•   Find out more about our role in developing the vaccine

Coronavirus samples inform national COVID-treatment guidelines

• Sotrovimab was one of the first anti-viral therapies licensed for the treatment of COVID-19 and an essential defence for people who have a poorer response to vaccination. However, by 2022 there was concern sotrovimab may not respond to newer variants circulating
• Led by researchers at the MRC-funded Francis Crick Institute, the Legacy Study utilised a unique bank of more than 400,000 coronavirus samples that had been collected since 2020 to test a variety of therapies
• They were able to show sotrovimab offered protection against newer strains. As a result, NICE issued guidelines for its continued use

UK Biobank provides evidence of COVID-19 brain changes

• Brain scans from UK Biobank – a database established by MRC with genetic and health information from 500,000 UK participants – revealed how even mild COVID-19 infection can cause physical changes to the brain
• The UK Biobank COVID-19 Repeat Imaging study enabled researchers to access brain scans of individuals around three years apart, making it the only study in the world to demonstrate ‘before and after’ changes in the brain associated with SARS-CoV02 infection
• The results showed participants who contracted COVID-19 had a greater reduction in brain size compared to uninfected participants. UK Biobank will be a vital resource in understanding whether these changes are reversible over time

UK Biobank participant undergoing a brain scan as part of the UK Biobank COVID-19 Repeat Imaging study. Credit: UK Biobank

MRC improving UK health and wellbeing

Lifesaving treatments for neuromuscular diseases in children

• More than two million children worldwide are affected by neuromuscular diseases
• Work funded by MRC and medical research charities, in collaboration with biotechnology companies, led to approval of the first effective treatments for the genetic diseases Duchene Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA)
• Researchers from UCL, Royal Holloway and Bedford New College developed Spinraza – the only approved drug for the treatment of SMA in the UK and most of the world – available via the NHS since June 2019, with 300 patients already gaining access
• Two medicines developed for DMD – Exondys 51 and Vyondys 53 – which improve quality of life and life expectancy for at least 20% of patients, approved in the US and benefitting over 1,500 people so far
• These medicines have also generated sales of more than $5.5 billion

Cell discovery offers potential new asthma treatment

• The discovery of a type of immune cell could provide a valuable new tool for treating asthma
• Researchers at the MRC-funded Laboratory of Molecular Biology discovered cells that secrete an inflammatory molecule, interleukin-13 (IL-13), which can trigger a reaction in asthma patients. The release of IL-13 is activated by interleukin-25 (IL-25)
• Scientists developed a therapy to block the action of IL-25, preventing it from activating IL-13 and triggering an asthma reaction. A clinical trial is underway to establish its use in treating asthma. The therapy also has potential in the treatment of colorectal cancer

Microscope images of a mouse intestine showing smaller cancers and a more active immune response when ILC2 immune cells are blocked or removed. Credit: MRC Laboratory of Molecular Biology

Repairing damaged cartilage in knee joints

• Left untreated, defects in cartilage can progress to osteoarthritis. A team of researchers at the University of Keele has developed a cell therapy that helps repair cartilage in knee joints
• An MRC-funded trial provided the evidence and cost-benefit data that led to the therapy, known as autologous chondrocyte implantation, which received NICE approval in 2017. The team also developed a tool to help identify patients who would most benefit from the treatment
• The team are currently investigating a new ‘off the shelf’ cell therapy that uses donor cells, which would reduce cost and improve patient outcomes

MRC improving outcomes for cancer patients

Anti-cancer treatments across the world

• University of Southampton developed anti-cancer monoclonal antibodies. The most advanced are two used to treat leukaemias such as Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL) called Ofatumumab and Obinutuzumab
• The patented research was collaboratively developed and licensed to a Swedish biotech firm, resulting in a clinical trial programme that led to a £73 million commercial agreement
• MRC funding has supported this field of research since the 1970s when scientists at the MRC LMB discovered monoclonal antibodies and later developed humanised monoclonal antibodies in the 1990s for which they won Nobel prizes

Trial improves prostate cancer patient health and care

• Research led by the Universities of Oxford and Bristol has changed the way that men with early-stage prostate cancer are diagnosed and treated
• The ProtecT trial compared active monitoring with more invasive treatments, radiotherapy and surgery, finding that patients who did not undergo invasive treatment had the same high survival rates
• The trial also found that the negative impacts of radiotherapy and surgery on urinary and sexual function persist much longer than previously thought – for up to 12 years
• Evidence has changed health policy and clinical practice through updated guidelines and optimised treatment
• MRC funding has supported the underpinning work carried out at the University of Bristol through the MRC ConDuCT-II Hub since 2014

MRC supporting healthy ageing

Preventing falls in older people

• Falls are a significant concern for older people and come at a cost of more than £2.3 billion per year to the NHS
• Home adaptation services – such as stairlifts, grab-rails and ramps – are available for those who want to continue living in their home. However, until now, there has been no evidence to demonstrate their effectiveness
• Researchers from the MRC-funded Health Data Research UK have created a dataset that shows these adaptations can help prevent falls and also identifies those most at risk of falling. The research could help inform policy for proactive interventions

Identifying genetic risk of Alzheimer’s disease

• An international study has identified 75 genes associated with an increased risk of developing Alzheimer’s disease, including 42 new genes that had not previously been implicated
• Researchers at the MRC-funded UK Dementia Research Institute analysed the genomes of 111,326 people diagnosed with Alzheimer’s disease and 677,633 genomes from healthy people, making it the largest genetic study of Alzheimer’s disease to date
• The development of a new genetic risk score could be used when recruiting patients for clinical trials aimed at treating the early stages of the disease, when damage to the brain is minimal

Brain inflammation with microglia that fail to clear debris, causing astrocytes to react. Credit: National Institute on Aging, National Institutes of Health

MRC informing health policy

Big data to improve care and outcomes for millions of people with cardiovascular disease

• UCL researchers used large-scale patient data to shape national and international clinical guidelines for the prevention, diagnosis, and treatment of a range of cardiovascular diseases. This has benefitted care and improved outcomes for millions of patients worldwide
• Evidence from the research informed a major change in guidelines, to lower the blood pressure threshold which defines hypertension, making diagnosis more accurate
• MRC funding has contributed to this research since 2012

Understanding the transmission and control of COVID-19

• Research from Imperial College London and Oxford University provided key data which underpinned recommendations and policies during the COVID-19 pandemic. This included school closure policy, social gatherings and contributed to the recommendation of interventions to protect those living in large households
• The evidence transformed our understanding of the epidemiology of COVID-19 and the measures required to protect public health
• MRC Centre for Global Infectious Disease Analysis (GIDA) scientists have tailored their research focus to COVID-19 to provide rapid, open access, real-time modelling and assessment analysis targeted at the needs of policymakers
• Since its establishment in 2008, MRC GIDA scientists provided insight into previous outbreaks of Ebola and Zika and worked with public health agencies and policy makers to improve preparedness and responses to disease outbreaks

Genome sequencing to inform outbreak response

• Researchers at the University of Birmingham developed rapid whole genomic sequencing methods to transform the management of infectious disease around the world
• The research has improved identification of transmission pathways, evolution of pathogens and sites of persistence. MRC funding supported the team to apply rapid genome sequencing to pathogens such as Ebola, Zika and SARS-COV-2
• In addition, MRC-funded research at the University of Oxford was crucial in the development of the MinION sequence platform – a ‘pocket sequencer’ that enables rapid analysis of data in the field – and the creation of spin-out company Oxford Nanopore Technologies

MRC improving health globally

Protecting human health from infectious disease in low-resource settings.

• Research from the University of Brighton has contributed to reducing human health risk from diseases including cholera, ebola, typhoid, and childhood diarrhoea in regions of Africa, Asia, and South America
• The Brighton team helped the National Institute of Cholera and Enteric Diseases to prioritise effective public health interventions in urban slum districts in India (home to 100,000 people) and the Kenyan Medical Research Institute to protect 1,170 rural inhabitants
• This research was supported by MRC in 2017 in a project which quantified routes of microbial contamination between livestock and drinking water

Improving treatment of meningitis in developing countries

• Cryptococcal Meningitis is a major cause of HIV-related deaths in developing countries, accounting for more than 180,000 deaths per year. Previous treatments involved costly medications and regular monitoring in hospitals
• Researchers at the University of Oxford, Liverpool School of Tropical Medicine, London School of Hygiene and Tropical Medicine and St. Georges, University of London demonstrated the efficacy of low-cost antifungal drug flucytosine. The WHO implemented the findings into their guidelines, which reduced costs, improved access, and led to reductions in mortality
• MRC-funded research supported key clinical trials to determine the optimum combinations of flucytosine, providing the evidence needed for implementing these guidelines
• The findings also led to a $20 million investment from global health organisation UNITAID, benefiting seven African countries

Our mission is to improve human health through world-class medical research. To achieve this, we support research across the biomedical spectrum, from fundamental lab-based science to clinical trials, and in all major disease areas. We work closely with the NHS and the UK health departments to deliver our mission, and give a high priority to research that is likely to make a real difference to clinical practice and the health of the population. Together, we:

• encourage and support research to improve human health
• produce skilled researchers
• advance and disseminate knowledge and technology to improve the quality of life and economic competitiveness of the UK
• promote dialogue with the public about medical research

Further information

Explore more impacts arising from MRC-funded research

Find out more about MRC

Internet Explorer is no longer supported by Microsoft. To browse the NIHR site please use a modern, secure browser like Google Chrome, Mozilla Firefox, or Microsoft Edge.

NIHR awards £42m to new centres to develop innovative technology solutions to improve healthcare

Published: 13 November 2023

The NIHR has awarded almost £42 million (£41,790,690) to establish 14 new centres across England that will drive life-changing research into health technologies.

From 1 April 2024, the 14 new NIHR HealthTech Research Centres (HRCs) will work with businesses to support the development of medical devices, diagnostics and digital technologies.

These technologies will enable people to:

• better monitor their health
• diagnose ill health sooner
• improve management of conditions including cancer, dementia, cardiovascular and respiratory disease

The HRCs will also work with companies to develop and test products to support rehabilitation and help those with social care needs to maintain their independence. They will work closely with carers, patients and users at all stages.

Each HRC will be hosted by an NHS organisation in England, bringing industry, academia and the health and care system together. The HRCs will:

• drive innovation and efficiency
• bring new technologies to those who need them most
• support the health and care workforce to reduce workload
• help alleviate pressures on the health and care system

The HRCs will keep the UK at the forefront of research and the place companies want to come to in order to invest in the development of health technologies.

Health and Social Care Secretary Steve Barclay said:

“These centres will help bring the latest advances in medical technology into patients’ lives sooner improving care, treatment and diagnosis including for those with cancer, dementia and brain injuries.

“We are already seeing the benefits of previous investment in health technologies - such as using artificial intelligence to predict how different patients respond to medication for inflammatory bowel disease meaning the right treatment is provided to patients sooner.

“I look forward to seeing what our world leading scientists, clinicians and inventors bring forward next.”

The HRC scheme replaces the successful NIHR Medtech and In Vitro Diagnostic Co-operative (MIC) scheme, which comes to an end in March 2024.

The previous scheme delivered significant impact, including the development of:

• Virtual reality rehabilitation physiotherapy for children. This enabled them to undergo treatment from the comfort of their own home, reducing pressures on hospital services;
• The “HeadUp Collar”. This drastically improves the quality of life for people with motor neurone disease. It addresses problems with communication, swallowing, breathing, mobility and pain;
• A breath test for multiple gastrointestinal cancers. This enables detection at an earlier stage, when treatments are more effective;
• QbTest, a computerised assessment of attention deficit hyperactivity disorder (ADHD). This is now used in NHS ADHD Clinics in England to support clinical decision making and more efficiently diagnose ADHD. QbTest enables people to have fewer consultations and receive support much earlier.

The new scheme will continue to support innovative projects like these. It will also build capacity and expertise to support the development of health and care technologies to meet growing demand. The HRCs will develop technology for hospitals and in general practice as well as for use within community and social care settings. This will enable patients to benefit from these innovations wherever they come into contact with the health and care system.

Professor Lucy Chappell, Chief Scientific Adviser to the Department of Health and Social Care and CEO of the NIHR, said:

“Research into health technology is recognised as being of vital importance for patients, carers and users, our workforce, and the wider health and care system.

“The establishment of the NIHR Healthtech Research Centres shows our firm commitment to driving innovation in healthtech research from conception through to adoption.

“Our existing research centres in MedTech have delivered new technologies that have helped prevent, diagnose and treat ill health for many individuals, as well as ensuring increased efficiencies in the health and care system.

“The increased funding for the HealthTech Research Centres will build capacity and  expertise in health technologies, bring new innovations to market and enable people to live healthier, better-quality lives.”

The funding will support government priorities including:

• Levelling up across the country. Nine of the 14 HRCs will be based at NHS organisations outside the Greater South East. They will receive the majority of the funding (64%).
• The HRCs will support the development of innovations that address the most pressing healthcare challenges, including cancer, mental health, neurodegeneration and dementia, ageing, respiratory disease, and cardiovascular conditions.
• The HRCs will support industry, including small and medium sized enterprises and local innovation clusters, to develop new medical technologies and diagnostics, and increase the chance of adoption in the NHS and other health and care settings. This will further cement the United Kingdom as a leading global hub for Life Sciences.
• The HRCs will support delivery of the Government's medical technology (“medtech”) strategy. Medtech is of vital importance to the UK health and care system, helping people live more independent, healthier lives for longer.

Here is a full list of the new HRCs:

Latest news

New findings on the use of molnupiravir to treat COVID-19

New funding opportunities for novel brain tumour research launched

ADHD digital test approved for use by the NHS

NIHR welcomes £300m investment into clinical trials infrastructure bringing new medicines to patients across the UK

First UK lung cancer patient receives novel immune therapy at NIHR Clinical Research Facility

Plans approved for UK Centre for Medical Research and Innovation

Plans to build a world-leading medical research institute at St Pancras in London have been approved by councillors at Camden Town Hall. The UK Centre for Medical Research and Innovation (UKCMRI), designed by the architects HOK with PLP Architecture, will have 1500 staff, including 1250 scientists.

• Share with Facebook
• Share with X
• Share with LinkedIn
• Share with Email

UKCMRI is founded by the Medical Research Council, Cancer Research UK, the Wellcome Trust and UCL (University College London).

The members of the Development Control Committee voted in favour of the £500 million project at a meeting at the Town Hall on 16 December.

Chief Executive of Cancer Research UK, Harpal Kumar, welcomed the decision: "The councillors have brought this institute significantly closer to reality. It will help to tackle some of the most difficult scientific and medical questions - bringing benefits to health and helping us to treat and beat diseases that affect us all, including cancers, heart disease and stroke, infections and diseases of the immune and nervous systems. It will bring benefits to health and be a national resource for the training and development of scientists. It will engage the public in its work and will provide educational benefits to schools locally and nationally."

Sir David Cooksey, Chairman of UKCMRI, added: "UKCMRI will harness the talent and potential of doctors, nurses, biologists, mathematicians, physicists, chemists, computer scientists and engineers to understand the underlying causes of disease. This will accelerate our ability to treat disease - bringing benefits to patients through the NHS and to the economy by developing a sector in which the UK already excels."

In October, the Government gave its commitment to UKCMRI by confirming its investment in the project through the Medical Research Council. Prime Minister David Cameron announced that UKCMRI would have a central role in the Government's National Infrastructure Plan to ensure the UK remains a world leader in science and research. Over half the funds are being contributed by Cancer Research UK, the Wellcome Trust and UCL.

The construction of UKCMRI is expected to begin in the spring with completion in 2015.

Share this page

Global main menu

• Research Centres

Centre for Cardiovascular Medicine and Devices

The Centre for Cardiovascular Medicine and Devices  has been created to bridge the gap between academics and clinicians in their endeavour to innovate in translational medicine.

The Centre houses a productive transatlantic relationship with Yale University which focuses on research and innovation. Our projects include next-generation stent technology and big data consolidation. Our Yale colleagues include Prof. Alexandra Lansky, one of the Centre’s research leads, alongside Prof. Carlos Mena-Hurtado, Prof. John Forrest and Prof. Eric Velasquez. The Centre also has a strong working relationship with Prof. Bernard Gersh, based at the Mayo Clinic.

The Cardiovascular Devices Hub (CVDHub) sits within this Centre. The CVDHub, partly funded by the ERDF, supports collaborations between academic, clinical, engineering and industrial innovators to develop clinically and commercially viable cardiovascular devices. This novel, cross-speciality unit helps small to medium enterprises (SMEs) over the hurdles involved in taking new innovations to human trials. We are currently building a new space for collaborative interaction which will include flexible meeting and conference facilities.

The overall research objectives of this internationally acknowledged group are:

• Mathur : Role of biologics (stem cells, gene therapy) in the treatment of CV disease. Use of advanced cardiac imaging to examine mechanistic aspects of translational research. Novel devices, first in man trials, device innovation, digital technologies (e.g. Avatars), artificial intelligence, megakaryocyte biology, and the role of platelets in cardiovascular disease.
• Ahluwalia : Effects of nitrite and nitrate on the cardiovascular system, sex differences in cardiovascular function and disease, the role of TRPV1 in vascular reactivity.
• Baumbach : Clinical evaluations of device-based embolic protection to reduce stroke during cardiovascular interventions, definitions of endpoints for neurological injury in cardiovascular trials, new stent technology, first in man use of novel device concepts.
• Lansky : The clinical impact of silent embolic events and consequences on neurocognitive function following TAVR procedures.

Principal Investigators

• Professor Anthony Mathur , Centre Lead
• Professor Amrita Ahluwalia , Deputy Centre Lead (WHRI)
• Professor Andreas Baumbach , Deputy Centre Lead (Barts Heart Centre)
• Professor Alexandra Lanksy , External Scientific Advisor
• Dr Vikas Kapil , Senior Lecturer and Centre Education Lead
• Dr Dan Jones , Senior Lecturer
• Dr Vahitha Abdul Salam , Lecturer
• Dr Claudio Raimondi , Lecturer
• Dr Krishnaraj Rathod , Senior Clinical Lecturer
• Dr Christos Bourantas, Honorary Senior Lecturer
• Professor Charles Knight , Honorary Chair 
• Professor Richard Schilling , Honorary Chair 
• Professor Peter Groves, Honorary chair

Overseas Faculty

• Professor Eric Velasquez (Yale)
• Professor Carlos Mena-Hurtado (Yale)
• Professor Bernard Gersh (Mayo Clinic)
• Dr Didier Locca, Honorary Reader, QMUL ( EPFL, Swiss Institute of Technology)

News & Events

• Collaborative conference with Chonnam National University
• Cardiovascular MedTech Innovation with the CVDHub: How to Run a Successful Clinical Trial and The Future Post-Brexit & Post-Pandemic
• HR: [email protected]  
• Centre Administrator: Tania Begum, [email protected]
• PA to Prof. Ahluwalia: Zahra Salim, [email protected]  
• PA to Prof. Lansky: Soni Cox, [email protected]
• PA to Profs Baumbach & Mathur: Alice Reid, [email protected]  

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

The PMC website is updating on October 15, 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• J R Soc Med
• v.114(1); 2021 Jan

Advancing UK regulatory science and innovation in healthcare

Melanie j calvert.

1 Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TT, UK

2 National Institute for Health Research (NIHR) Applied Research Centre West Midlands, Birmingham B15 2TT, UK

3 NIHR Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham B15 2TT, UK

4 Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham B15 2TT, UK

5 Health Data Research UK, London NW1 2BE, UK

Eliot Marston

Mark samuels.

6 Lifesci Ltd, London WC2H 9JQ, UK

Samantha Cruz Rivera

Barbara torlinska, kathy oliver.

7 International Brain Tumour Alliance (IBTA), Tadworth KT20 5WQ, UK

Alastair K Denniston

8 University Hospitals Birmingham NHSFT, Birmingham B15 2GW, UK

9 Regulatory Horizons Council London SW1H 0ET, UK

Steve Hoare

10 The Association of the British Pharmaceutical Industry, London SW1E 6QT, UK

As the UK exits the European Union, there is a pressing need for the UK to invest in regulatory science and innovation if it is to be globally competitive and internationally collaborative. Innovation in life sciences, including digital tools, robotics, artificial intelligence and new therapeutic approaches, such as cell and gene therapy, will play a crucial role in continued improvement in health outcomes and life expectancy. The UK is powerfully positioned to lead in the discovery, development and evaluation of these new approaches, enabling accelerated routes to market, increasing benefits to public and individual health, improving patient safety, influencing international practice and promoting investment in the UK. 1 , 2

Advances in regulatory science, or ‘the application of the biological, medical and sociological sciences to enhance the development and regulation of medicines and devices in order to meet the appropriate standards of quality, safety and efficacy’, 3 matter more than ever to inform and evaluate new approaches to regulating these innovative technologies. In this commentary piece, we argue that the UK has a unique opportunity to advance regulatory science and innovation and drive global advances in this area and make a series of recommendations to this end based on key findings from Birmingham Health Partners Advancing Regulatory Science and Innovation in Healthcare Report (Box 1). 4 , 5 The UK should take a coordinated approach to foster and prioritise advances in regulatory science and innovation and build a workforce to ensure its sustainability and continuing evolution. We should actively support the emergence of both existing and new clusters in regulatory science. Support for these clusters should draw on world-leading academic expertise, leverage increasingly integrated regional ecosystems, connecting industry, policy and the NHS and – crucially – the voices of our patients and citizens (Box 2).

Recommendations. a

a Recommendations taken from Birmingham Health Partners Advancing Regulatory Science and Innovation in Healthcare Report, 2020, based on a scoping review and stakeholder input. 4 MHRA: Medicines and Healthcare Products Regulatory Agency; R&D, research and development.

Current context for regulatory science

Life sciences are vital to the UK’s health but also its economic wealth. The industry supports around 482,000 jobs in the country and the activities of life sciences companies directly contributed £14.5bn to the national economy in 2015, with an additional £15.9bn provided through the life sciences supply chain and employee spending. 6 UK life sciences businesses face unprecedented challenges in both near-term viability and long-term sector sustainability due to regulatory uncertainty following Brexit and the global COVID-19 pandemic.

As a European Union member, the UK Medicines and Healthcare Products Regulatory Agency was integrated in the European Union Medicines Regulatory Network, including the European Medicines Agency. Now that the UK has left the European Union, the Medicines and Healthcare Products Regulatory Agency will ‘continue to support the UK Government to deliver its legal obligations under the Withdrawal Agreement and prepare for its new relationships with the European Union and the rest of the world’. To do this, they continue to work closely with the Department of Health and Social Care to ensure the UK regulatory environment works in the best interests of patients, industry and our partners across the health and care system.’ 4 , 7 The Medicines and Healthcare Products Regulatory Agency Business Plan 2020–2021 highlights key strategic areas for change ‘in response to the need to develop a new and effective regulatory model, but this also reflects a new focus on involving and engaging with patients, enabling patient access to new innovative medicines and devices, and speedier response to risks to patient safety and public health.’ 7 A key strategic objective is to improve regulatory science. Post-transition, we should use the European Union–UK negotiations to maintain their current high level of regulatory compatibility, while contributing to advancing global regulations. How should the UK do this? First, it must take account of clear clinical and academic strengths to inform regulatory innovation. Second, it must factor in the opportunity for UK industry to invest in innovation and create a national testbed to drive global progress.

The life sciences industry has already invested significant effort and funds to prepare for new European Union frameworks, and incompatibility from the UK brings risks around complexity, competence and capacity. Our UK trade associations – providing insight and ongoing engagement – have given us a robust framework that we should harness to mitigate these risks. The Government’s White Paper on ‘Regulation for the Fourth Industrial Revolution’ noted that:

We need to reshape our regulatory approach so that it supports and stimulates innovation that benefits citizens and the economy. At present, only 29% of businesses believe that the government’s approach to regulation facilitates innovative products and services being efficiently brought to market. The need for reform is urgent: 92% of businesses from a range of sectors think they will feel a negative impact if regulators don’t evolve to keep pace with disruptive change in the next two to three years. 1

COVID-19 has severely impacted life sciences research and development, while also demonstrating the impact of a more collaborative effort and regulatory flexibility. The sector is looking at resilient recovery while recognising the continued risk of disruption. During this recovery phase, pharmaceutical and medical technology companies have asked for continued, (national and international) regulatory flexibility. They have used flexibility as they accelerate product development in medicines, devices and vaccines, and move to re-initiate trials, mitigate missing data and implement new models of working (including telehealth and remote monitoring). The unprecedented events of the pandemic have offered a paradigm shift in healthcare regulation. 8 , 9

Strategic leadership and coordinated support

The UK Government’s White Paper, Regulation for the Fourth Industrial Revolution, notes:

As we leave the European Union and forge a new path for ourselves, we will continue to play an important role in shaping how regulation is developed internationally. We will collaborate with like-minded international partners to reduce regulatory barriers to trade, through mechanisms such as the adoption of international standards, mutual recognition agreements and free trade agreements. We will encourage our regulators to play an active role in shaping international thinking on how innovation should be regulated. 1

For the UK to maximise opportunities in the future regulation of healthcare innovation, it must work cohesively and collaboratively while creating an environment that gives innovators faster ways to demonstrate benefit. The UK must leverage the high profile and excellent stakeholder engagement processes of the leading players. These organisations include: the NHS, patient organisations, National Voices, academia, the Medicines and Healthcare products Regulatory Agency, the NICE and Health Research Authority, as well as the Association of the British Pharmaceutical Industry, Association of British HealthTech Industries, Accelerated Access Collaborative, the British In Vitro Diagnostic Association and Health Data Research Alliance, coordinated by Health Data Research UK, which aims to establish best practice around the ethical use of UK health data for research and innovation at scale. 10 Expert regulatory science should support them.

To gain these crucial inputs, we will need collaboration across multiple stakeholders and strategic leadership. Meaningful patient and citizen involvement should be central to all activities (Box 2). Additionally, we require alignment with the new Regulatory Horizons Council. 11 This independent expert committee identifies the implications of technological innovation; it provides the government with impartial, expert advice on the regulatory reform required to support the rapid and safe introduction of new technologies.

The need for meaningful and sustained patient and citizen involvement.

The growth of the Academic Health Science Networks has complemented the emergence of significant academic–NHS partnerships. 12 Additionally, Life Science Opportunity Zones support major industry-facing centres of gravity. Together, these areas have become ready-made research ‘clusters’ for innovation – and an ideal springboard for regulatory science to flourish in the UK. 13 Through increased ease of collaboration, clusters foster shared knowledge and talent pools, support collaborative cross-sector innovation and generate synergistic value. They provide essential accelerators and testbeds to inform broader systems thinking.

An ongoing commitment to international collaboration will also be key. It would be highly damaging for the UK to attempt to operate fully in isolation of other regulatory systems and international excellence in approaches to supporting emerging technologies and regulatory science. 2 Indeed, we can and should learn from global regulatory science initiatives such as the research programmes and centres of excellence supported by the Food and Drug Administration (FDA) in the US and the Clinical Trials Transformation Initiative. 5 , 14

Prioritisation and shared risk

Regulatory science – where appropriately targeted – offers a way to provide clarity and collaboration between stakeholders. There are several emerging technologies and trends in regulation which need collective visions on how best to move forward, as highlighted by recent Regulatory Science Summits organised by the Innovative Medicines Initiative in collaboration with the European Medicines Agency and FDA and the European Medicines Agency’s Regulatory Science to 2025 strategy. 15 , 16 These technologies include: advanced therapy medicinal products, artificial intelligence, digital tools for data collection and analysis, digital therapeutics, immunology and the microbiome, big data and digital health, as well as real-world evidence and clinical trials.

International horizon scanning should proactively identify emerging healthcare technologies. Where uncertainties arise about appropriate regulation, we need joint working processes that enable regulatory bodies and industry to flag where evidence and innovation are required in regulatory science to justify research and development investments. Interaction with patient organisations and enhancing methods to incorporate patient-relevant evidence in benefit-risk evaluation and regulatory decision making is key. Tools include patient-reported outcomes and patient preference data. 15 Products, services and business models with high potential benefit for UK society and the economy should be prioritised. Innovation in regulatory science is vital to underpin a research and development environment that mitigates ‘high-risk’ areas of investment with significant promise, such as antimicrobial resistance or new medications for pregnancy-related conditions, to facilitate the rapid and safe introduction of these products and services. 17 Early engagement of innovative developers with multi-stakeholder scientific advice (for example, joint meetings offered by the Medicines and Healthcare Products Regulatory Agency Innovations Office and NICE), offers benefits to all; facilitating navigation of the regulatory landscape and identifying challenging areas for regulators to address. 18

Implementation and evaluation of regulatory innovation

New tools and methodologies will be needed to properly evaluate the impacts of regulatory change and support continuous iteration – the building blocks for these have already been established nationally and internationally. In 2012, the Organisation for Economic Co-operation and Development (OECD) published a framework for systematically evaluating the performance of regulations and regulatory policies. 19 Measuring regulatory progress in a meaningful and credible way requires indicators to measure relevant outcomes and appropriate research designs. Both are needed to support inferences about the extent to which a regulation or regulatory policy under evaluation has actually caused a change in the measured outcomes. Indicators may include: (1) impact/effectiveness (changes in the problem or other outcomes of concern such as patient safety, mortality); (2) cost-effectiveness (costs for a given level of impact); (3) net benefits (all beneficial impacts minus all cost impacts); and (4) equity/distributional fairness of impacts. In addition to equity or distributional concerns, sometimes other outcomes of interest are used as criteria, such as impacts on technological innovation, macroeconomic growth, and employment. Building on the Organisation for Economic Co-operation and Development framework, the European Medicines Agency has developed a conceptual framework for the review of the impact of regulatory science projects on its regulatory processes and activities – with implications for resources and further iterative improvements (Box 3). 19

We believe that we need ‘parallel not series’ evaluation, regulation and implementation processes, underpinned by training. Additionally, we require development platforms that: bring together innovators, regulators and end-users to map out innovation journeys; create consensus for the use of novel technologies; devolved flexibility to enable real-world testing of regulatory adaptation before scaling nationally.

European Medicines Agency conceptual framework for the review of the impact of regulatory science projects on regulatory processes and activities.

Workforce development

Developing a coherent UK programme of training in regulatory science will be crucial to delivering workforces for industry, the NHS, policy and academia and to support patients and the public involved in regulatory science initiatives. This is an urgent priority to bridge the potential expertise gap resulting from leaving the European Medicines Regulatory Network and to advance regulatory science in the UK. It will provide a sustainable skills pool to ensure that technological innovation in healthcare can be supported successfully – and the corresponding health and economic benefits are realised – while robustly protecting patients. However, we also need to understand what each of these diverse stakeholders in regulatory science need – and what they can offer – so that we can assemble a clear national framework and strategy. Current UK-based training is somewhat limited, comprising master’s level training/apprenticeships and continuing professional development, emerging technologies will require a higher level of capability. 20 To keep pace with innovation and international counterparts, the programme needs to be expanded via internships, fellowships and PhDs involving academia, industry, professional bodies, National Health Service and regulatory bodies as key collaborators, mentors and beneficiaries. The UK should seek to establish clear career pathways in regulatory science.

The UK can learn from, and engage with, international initiatives. In the US, the FDA offers a programme of internships and fellowships via its Oak Ridge Institute for Science and Education partnership. 21 The programme allows the FDA to target and accelerate key areas of regulatory science which will support its future activities with successful Fellows often going to work for the regulator and in turn mentoring future Fellows. In the European Union, the European Medicines Agency is currently designing two curricula through the Strengthening Training of Academia in Regulatory Science ‘STARS’ initiative to support both the professional training of clinical scientists and a broader programme to support a shared post graduate educational agenda, 22 while the global association for people working in Regulatory Affairs (TOPRA) offer significant training opportunities for professionals. 23 It will be crucial to leverage their expertise, insights and professional standing to create an appropriately competitive and ambitious, forward-looking training programme for the UK.

Underpinning the advancement of the sector is also a need for people with regulatory skills, across industry, the health service and academia as well as regulators, not only to do the core work of medicines development, regulation and delivery to patients but to be resourced to develop standards for emerging technologies and methodologies. 2

The UK’s current situation brings significant complexities, challenges and risks. However, our uniquely collaborative and dynamic national ecosystem for regulatory science is more than capable of rising to tackle them and ensuring this is the time of unique opportunity and benefit.

Why do these proposals matter? We have recommended actions that – crucially – can put the UK in a leadership position for regulation. This position will attract the most exciting ideas and strategic resources from the global industry. It will further accelerate the co-creation and adoption of innovation by the NHS. Critically for regulators, it will create all-important academic insights into the tools, technologies and methodologies they need. And most importantly, it will give our patients and the public an integral voice in the design, development and delivery of innovative new treatments, diagnostics and medical devices. This is an opportunity to develop our regulatory science strategy for the UK to benefit the world.

Provenance: Provenance: Not commissioned; the paper was revised following peer review comments from another journal

ORCID iD: Melanie J Calvert https://orcid.org/0000-0002-1856-837X

Declarations

Competing interests.

KO states that she has no real or perceived conflicts of interests with regard to her co-authorship of this paper but for the sake of transparency she states the following: Between 2005 and 2020, the IBTA has received unrestricted educational grants and financial support and/or support in kind either as an individual organisation or as part of a wider grouping of patient organisations, from the following companies and trusts: AbbVie, Accuray, Antisense Pharma, Apogenix, Archimedes, Ark Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Brain Tumor Network (USA), Brain Tumor Resource and Information Network (USA), Bristol-Myers Squibb (BMS) Celldex Therapeutics, Celgene, Crusade, Dijon Designs (UK), Elekta, Eli Lilly, Gerry & Nancy Pencer Brain Trust (Canada), Gosling Foundation (UK), GlaxoSmithKline (GSK), GW Pharmaceuticals, Incyte, Ivy Foundation (USA), Lilly, Link Pharmaceuticals, MagForce, Medac, Merck Serono, Merck, MGI Pharma, MSD Oncology, NeoPharm, Neuroendoscopy (Australia), Northwest Biotherapeutics, Novartis, Novocure, Pediatric Brain Tumor Foundation (USA), Pfizer, Photonamic, Roche, Schering-Plough (Global), Sontag Foundation (USA), Spink (UK), STOPheresetumoren.nl, to-BBB, Vane Percy (UK), VBL Therapeutics and the Wallerstein Foundation (USA). KO, on behalf of Kathy Oliver Consulting, has also in this same period received consultancy fees from Lilly, GSK, Bayer, SPAEN and Novartis. For further details of the IBTA’s sponsorship policy, please see https://theibta.org/become-a-corporate-sponsor/ . MC has received personal fees from Astellas, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work.

SH is an employee of the Association of the British Pharmaceutical Industry. MS, BT and SCR declare no conflict of Interest.

The Birmingham Health Partners Advancing Regulatory Science and Innovation in Healthcare Report and this commentary piece were funded by a Quality-related (QR) research grant from Research England.

MJC is a National Institute for Health Research (NIHR) Senior Investigator and receives funding from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham National Health Service Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma.

AKD receives funding from Health Data Research UK, an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. AKD also receives funding from the Wellcome Trust, the NIHR Biomedical Resource Centre (Moorfields Eye Hospital/UCL) and the Regulatory Horizons Council. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care, the Regulatory Horizons Council or the Department for Business, Energy and Industrial Strategy.

Ethical Approval: Not required

Guarantor: MJC.

Contributorship: This commentary piece is based on the Birmingham Health Partners Advancing Regulatory Science and Innovation in Healthcare Report 2020 4 and recommendations therein, which was co-authored by MS, EM and MJC. MJC prepared the initial draft of this commentary piece. All co-authors critically reviewed the manuscript and approved the final version. MJC is the Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation. KO is a patient advocate and Chair of the International Brain Tumour Alliance (IBTA). AKD is the Artificial Intelligence Lead for the Birmingham Heath Partners Centre for Regulatory Science and Innovation, and Director of INSIGHT, the HDRUK Health Data Research Hub for Eye Health. SH is the Quality, Regulatory Science and Safety policy director of the Association of the British Pharmaceutical Industry and thus represents the views of the research-based pharmaceutical industry in the UK. KO, patient advocate, contributed to writing the article, providing the content for Box 2 and contributing critical revisions to the manuscript at all stages.

Acknowledgements

We would like to thank contributors to the Advancing Regulatory Science and Innovation in Healthcare Report (Reference 4, page 73) from which this commentary is derived.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• My Bibliography
• Collections
• Citation manager

Save citation to file

Email citation, add to collections.

• Create a new collection
• Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

• Search in PubMed
• Search in NLM Catalog
• Add to Search

Opportunities and Risks of UK Medical Device Reform

Affiliations.

• 1 Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK.
• 2 Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
• 3 Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
• 4 National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK.
• 5 National Institute for Health Research (NIHR) Applied Research Collaborative West Midlands, University of Birmingham, Birmingham, UK.
• 6 Health Data Research UK, London, UK.
• 7 University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
• 8 Regulatory Horizons Council, London, UK.
• 9 Birmingham Health Partners Centre for Regulatory Science and Innovation, University of Birmingham, Birmingham, UK. [email protected].
• 10 Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK. [email protected].
• 11 Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. [email protected].
• 12 National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University of Birmingham, Birmingham, UK. [email protected].
• 13 NIHR Surgical Reconstruction and Microbiology Research Centre University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK. [email protected].
• 14 National Institute for Health Research (NIHR) Applied Research Collaborative West Midlands, University of Birmingham, Birmingham, UK. [email protected].
• PMID: 35416614
• PMCID: PMC9007047
• DOI: 10.1007/s43441-022-00394-0

Objectives: To identify the potential opportunities and risks around future UK regulatory reform of medical devices.

Design: A mixed methods approach, comprising a rapid literature review, one-to-one, semi-structured interviews with key stakeholders, a multidisciplinary stakeholder workshop, and a post-workshop survey.

Setting: United Kingdom.

Participants: 32 key stakeholders across the medical device sector were identified both from the public and private sectors.

Results: Opportunities relating to regulatory independence were identified, including the potential to create and implement a regulatory framework that ensures availability of medical devices; innovation and investment potential; and safety to the citizens of the UK. The most significant risks identified included threats to the safety of individual patients and the wider health system arising from the delay in awaiting regulatory approval due to the shortage of approved bodies; and reduced competitiveness of UK market and device manufacturers. Recommendations were identified to mitigate risks, centred on harnessing broader cross-sector collaborations, promoting patient and public partnership, and maximizing international engagement.

Conclusions: The UK's medical device sector is at a time-critical juncture to construct a regulatory framework to navigate its exit of Europe and respond to Europe's transition to new medical device regulations whilst also addressing the ongoing demand for rapid approval for new devices in response to the global pandemic. Investment, capacity-building, and international engagement will play a central role in mitigating risks and maximizing opportunities for medical device regulation.

Keywords: CE mark; In vitro diagnostics; Medical devices; Regulations; UKCA.

© 2022. The Author(s).

PubMed Disclaimer

Conflict of interest statement

OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Centre (ARC), West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences Ltd, and Janssen Pharmaceuticals, Inc. OLA declares personal fees from Gilead Sciences Ltd, GlaxoSmithKline (GSK) and Merck outside the submitted work. MC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for Patient-Reported Outcomes Research and is a National Institute for Health Research (NIHR) Senior Investigator. She receives funding from the NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB and GSK Pharma. MC has received personal fees from Astellas, Aparito Mltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centred Outcomes Research Institute (PCORI) outside the submitted work. AD is employed by University Hospitals Birmingham NHS Foundation Trust. He is also a Member of the Regulatory Horizons Council, Honorary Professor at University of Birmingham and Artificial Intelligence Theme Lead for the Birmingham Health Partners Centre for Regulatory Science and Innovation. His work undertaken on behalf of the Regulatory Horizons Council is funded by the Department for Business, Energy and Industrial Strategy. His research outside the submitted work is supported by grant funding from University Hospitals Birmingham NHSFT, NIHR HTA awards, the NIHR Biomedical Research Centre (Moorfields Eye Hospital NHSFT/University College London), Health Data Research UK, Medical Research Council and the Wellcome Trust. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or the Department of Business, Energy and Industrial Strategy. Other authors declare no competing interests.

Timelines for Post-Brexit UK legislation…

Timelines for Post-Brexit UK legislation for medical devices, in relation to EU Medical…

Similar articles

• Comparison of the international regulations for medical devices-USA versus Europe. Fink M, Akra B. Fink M, et al. Injury. 2023 Oct;54 Suppl 5:110908. doi: 10.1016/j.injury.2023.110908. Epub 2023 Jun 20. Injury. 2023. PMID: 37365092
• Medical device regulatory challenges in the UK are affecting innovation and its potential benefits. Beddoe-Rosendo J, Heaysman CL, Hajnal JV, Ourselin S, Vanhoestenberghe A. Beddoe-Rosendo J, et al. Proc Inst Mech Eng H. 2023 Nov;237(11):1243-1247. doi: 10.1177/09544119231203776. Epub 2023 Oct 15. Proc Inst Mech Eng H. 2023. PMID: 37840272 Free PMC article.
• Analysis of the renewed European Medical Device Regulations in the frame of the non - EU regulatory landscape during the COVID facilitated change. Kanti SPY, Csóka I, Adalbert L, Jójárt-Laczkovich O. Kanti SPY, et al. J Pharm Sci. 2022 Oct;111(10):2674-2686. doi: 10.1016/j.xphs.2022.07.011. Epub 2022 Jul 21. J Pharm Sci. 2022. PMID: 35872025 Review.
• Advancing UK Regulatory Science Strategy in the Context of Global Regulation: a Stakeholder Survey. Cruz Rivera S, Torlinska B, Marston E, Denniston AK, Oliver K, Hoare S, Calvert MJ. Cruz Rivera S, et al. Ther Innov Regul Sci. 2021 Jul;55(4):646-655. doi: 10.1007/s43441-021-00263-2. Epub 2021 Feb 16. Ther Innov Regul Sci. 2021. PMID: 33591566 Free PMC article.
• A Comparative Study of Medical Device Regulations:: US, Europe, Canada, and Taiwan. Chen YJ, Chiou CM, Huang YW, Tu PW, Lee YC, Chien CH. Chen YJ, et al. Ther Innov Regul Sci. 2018 Jan;52(1):62-69. doi: 10.1177/2168479017716712. Epub 2017 Jul 7. Ther Innov Regul Sci. 2018. PMID: 29714608 Review.
• Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience. Belgodère L, Emmerich J, Albin N, Bacon T, Daynes P, Vignot S, Vial T, Renaud G, Le Saulnier C, Maillard-Couvreur C, Cachet M, Veyries ML, Youdarene R, Oualikene-Gonin W, Ratignier-Carbonneil C, Maison P. Belgodère L, et al. Front Public Health. 2023 Nov 17;11:1293110. doi: 10.3389/fpubh.2023.1293110. eCollection 2023. Front Public Health. 2023. PMID: 38045969 Free PMC article.
• GHTF Study Group. Information Document Concerning the Definition of the Term “Medical Device” [Internet]. The Global Harmonization Task Force; 2005 May. Available from: http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n29r16-...
• Department for Business, Energy & Industrial Strategy. Life science sector data, 2020 [Internet]. GOV.UK ; 2021 [cited 2021 Jul 26]. Available from: https://www.gov.uk/government/publications/life-science-sector-data-2020
• Bioscience and Health Technology Sector Analysis 2019. Office for National Statistics; 2020.
• McHale JV. Health law, Brexit and medical devices: a question of legal regulation and patient safety. Med Law Int. 2018;18(2–3):195–215. doi: 10.1177/0968533218807255. - DOI
• UK Conformity Assessment [Internet]. GOV.UK . 2021 [cited 2021 Jul 2]. Available from: https://www.gov.uk/guidance/uk-conformity-assessment#combining-eu-and-uk...

Publication types

• Search in MeSH

Related information

Grants and funding.

• MC_PC_19005/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full text sources.

• Europe PubMed Central
• PubMed Central

• Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Cookies on Companies House services

We use some essential cookies to make our services work.

We'd also like to use analytics cookies so we can understand how you use our services and to make improvements.

You've accepted analytics cookies. You can change your cookie settings at any time.

You've rejected analytics cookies. You can change your cookie settings at any time.

We use cookies to make our services work and collect analytics information. To accept or reject analytics cookies, turn on JavaScript in your browser settings and reload this page.

Please press ENTER to search

UK CENTRE FOR MEDICAL RESEARCH AND INNOVATION LIMITED

Company number 03375849

• Company Overview for UK CENTRE FOR MEDICAL RESEARCH AND INNOVATION LIMITED (03375849)
• Filing history for UK CENTRE FOR MEDICAL RESEARCH AND INNOVATION LIMITED (03375849)
• People for UK CENTRE FOR MEDICAL RESEARCH AND INNOVATION LIMITED (03375849)
• More for UK CENTRE FOR MEDICAL RESEARCH AND INNOVATION LIMITED (03375849)

Last accounts made up to 31 March 2011

Nature of business (SIC)

• 7499 - Non-trading company

Forgotten your password?

First time user, if you have no login details and require access, you can..., registration is subject to approval, important: your previous staff log on will no longer work on this new site. colleagues will need to re-register as a first time user..

• WUTH Charity

Site Search

• Arrowe Park Hospital
• Clatterbridge Hospital
• Community locations
• Refreshment Facilities
• Having an operation (adults)
• Emergency and Urgent Care Update

Our Services

Please use the A-Z menu to find information about specific services.

• Women's Health
• Men's Health
• Children's Health
• Pregnancy & Babies' Health
• Sexual Health
• COVID-19 (Coronavirus)
• Support and Advice
• Health, Social & Care Worker Booster
• Healthy Wirral
• Your Inpatient Stay
• Mental Health
• Patient Portal
• NHS 111 First
• When to visit a pharmacy
• When to see your GP
• When to visit A&E
• When to see sexual health services
• When to care for yourself at home
• When to use a Walk-in Centre
• For Education and Development
• For Library and Knowledge Services
• For Research
• For Volunteering
• Key Documents and Information
• Diversity and Inclusion
• How We Use Your Information
• Awards and Accreditations
• Partnerships
• WUTH Website Privacy Notice
• Accessibility Statement
• Declarations of Interest
• Patient Experience
• WUTH Strategies
• Online Payments
• Growing your career with us
• Join our team
• Wirral as a place to live and work
• Apprenticeships
• Work Placements
• Equality and Diversity
• Quality Standards
• Raise a Concern, Speak Out Safely
• Vision and Values
• Volunteering
• Staff Stories
• Get in touch
• Departmental Contacts
• Feedback, Compliments, Concerns and Complaints
• Media Relations
• Ward Details
• Changing your details with us
• Freedom of Information Request
• Patient Messages
• Latest News
• Stakeholder Newsletter

New specialist centre puts Wirral on the map for clinical research

The launch of a new specialist research and innovation centre at Wirral University Teaching Hospital (WUTH)’s Clatterbridge site has put the trust firmly on the map as a growing centre of excellence for clinical research.

The Wirral Research and Innovation Centre will advance medical research at WUTH for the benefit of current and future patients, by embedding research into the care it provides.

WUTH’s Executive Medical Director, Dr Nikki Stevenson, said: “Clinical research is what drives improvements in healthcare. It’s one of our priorities as a hospital to try to find answers to healthcare challenges. It is our pledge to the Wirral population to play our part in finding new treatments and helping to address health inequalities. The Wirral Research and Innovation Centre is a major stride forward in our commitment to research.”

This new development has been made possible with funding from the North-West Coast Clinical Research Network (NWC CRN), which is the delivery arm of The National Institute for Health and Care Research.

NWC CRN’s Chief Operating Officer, Dr Chris Smith, said: “The Wirral Research and Innovation Centre will improve access to research that is relevant to people's healthcare conditions, and also act as a catalyst for further collaboration across Wirral and the wider Cheshire and Merseyside system. WUTH has a proud history of participating in nationally important research, and the launch of the centre today is a further step in delivering its strategy to improve healthcare through cutting edge research and innovation.”

The new centre has been designed to make the experience of research participants smooth, pleasant and safe, and the patient’s journey through the centre has been thought through carefully to ensure they are looked after in the most efficient and effective way.

The purpose-built facilities will be an attractive offering for life sciences companies looking to place research studies. It also provides a further opportunity to undertake research in combination with GPs and Wirral Community Health and Care NHS Foundation Trust, thus expanding the volume and breadth of study types carried out by WUTH.

Patients who attend the new centre will be those taking part in outpatient studies. Free parking will be provided, and participants will enter through a dedicated main entrance, and exit from another part of the building. The research and administrative staff area is located in a separate part of the centre to avoid any disruption to patients.

Simon Rogers, Clinical Lead for Research at the Trust, said: “Research provides the evidence that health professionals need to make the right decisions. It improves the quality of care we can provide. I’d like to say thank you to all the staff in the Trust who give their time to support the research studies we carry out. We’re also grateful to all the patients who take part in our research studies and influence the progress of new medical treatments. Without them none of it would be possible.”

Ask the publishers to restore access to 500,000+ books.

Internet Archive Audio

• This Just In
• Grateful Dead
• Old Time Radio
• 78 RPMs and Cylinder Recordings
• Audio Books & Poetry
• Computers, Technology and Science
• Music, Arts & Culture
• News & Public Affairs
• Spirituality & Religion
• Radio News Archive

• Flickr Commons
• Occupy Wall Street Flickr
• NASA Images
• Solar System Collection
• Ames Research Center

• All Software
• Old School Emulation
• MS-DOS Games
• Historical Software
• Classic PC Games
• Software Library
• Kodi Archive and Support File
• Vintage Software
• CD-ROM Software
• CD-ROM Software Library
• Software Sites
• Tucows Software Library
• Shareware CD-ROMs
• Software Capsules Compilation
• CD-ROM Images
• ZX Spectrum
• DOOM Level CD

• Smithsonian Libraries
• FEDLINK (US)
• Lincoln Collection
• American Libraries
• Canadian Libraries
• Universal Library
• Project Gutenberg
• Children's Library
• Biodiversity Heritage Library
• Books by Language
• Additional Collections

• Prelinger Archives
• Democracy Now!
• Occupy Wall Street
• TV NSA Clip Library
• Animation & Cartoons
• Arts & Music
• Computers & Technology
• Cultural & Academic Films
• Ephemeral Films
• Sports Videos
• Videogame Videos
• Youth Media

Search the history of over 866 billion web pages on the Internet.

Mobile Apps

• Wayback Machine (iOS)
• Wayback Machine (Android)

Browser Extensions

Archive-it subscription.

• Explore the Collections
• Build Collections

Save Page Now

Capture a web page as it appears now for use as a trusted citation in the future.

Please enter a valid web address

• Donate Donate icon An illustration of a heart shape

UK Centre for Medical Research and Innovation

Bookreader item preview, share or embed this item, flag this item for.

• Graphic Violence
• Explicit Sexual Content
• Hate Speech
• Misinformation/Disinformation
• Marketing/Phishing/Advertising
• Misleading/Inaccurate/Missing Metadata

Copyright is on the back cover.

plus-circle Add Review comment Reviews

Download options.

For users with print-disabilities

IN COLLECTIONS

Uploaded by Francesca Marchetti on June 14, 2022

SIMILAR ITEMS (based on metadata)

For students

• Current Students website
• Email web access
• Make a payment
• MyExeter (student app)
• Programme and module information
• Current staff website
• Room Bookings
• Finance Helpdesk
• IT Service Desk

Popular links

• Accommodation
• Job vacancies
• Temporary workers
• Future Leaders & Innovators Graduate Scheme

New and returning students

• New students website
• Returning Students Guide

Wellbeing, Inclusion and Culture

• Wellbeing services for students
• Wellbeing services for staff
• Equality, Diversity and Inclusion
• Israel, Palestine, and the Middle East
• Homepage challengers

Welcome to the University of Exeter

World class education and research in one of the most beautiful parts of the UK

Search for a course

US entry requirements

Virtual campus tours

Funding and Scholarships

Meet us in the USA

3 year Bachelors Go straight to your major

1 year Masters No GRE required

Rated Gold in the Teaching Excellence Framework (TEF) 2023

Scholarships available

150+ countries on campus

92% of graduates in or due to start employment or further study fifteen months after graduation HESA Graduate Outcomes Survey 2019/20

The Times and Sunday Times Good University Guide & Complete University Guide 2024

Russell Group Research intensive university

Delivering Green Solutions

Find out about Exeter’s leading work on positive tipping points and new Global Tipping Points Report in partnership with the Bezos Earth Fund.

Find out more »

Aerial view of the Streatham Campus, Exeter

Students working on Streatham Campus, Exeter

The Harbour Lights fish and chip shop in Falmouth

Interior of Exeter Cathedral

A traditional pub in Falmouth

The Forum, Streatham Campus, Exeter

Swanpool Beach in Falmouth

Reed Hall, Streatham Campus, Exeter

A lecture taking place in the Alumni Auditorium, Streatham Campus, Exeter

Rooftop bar in Exeter

Exeter Cathedral, built in 1133

Shopping in Princesshay, Exeter

One of many festivals that take place at Falmouth harbour

Paddleboarding and kayaking in Cornwall

 The University of Exeter Women's Rugby Club celebrate a win

World-famous St. Ives, a short drive from the Penryn Campus

Cross Keys Cafe on St Luke's Campus, Exeter

Brentor Church, Dartmoor, Devon

Aerial view of Penryn Campus and the coast

St. Luke's Fitness Centre

No Guts No Glory,  a lovely independent plant shop in Exeter

A student outside a local shop on Magdalen Road, near St Luke's Campus, Exeter

St Luke's Campus, Exeter

Stepcote Hill, Exeter

Independent shops on Fore Street, Exeter

Exeter Cathedral

Historic Exeter Quayside

The Cathedral Green, Exeter

The River Exe, Exeter

Traditional architecture in Exeter

Geology students in Cornwall

Physics students on the Streatham Campus, Exeter

Legendary Pizzas at Exeter's On the Waterfront restaurant

Latest News

Connect with us

Information for:

• Current students
• New students
• Alumni and supporters

Quick links

Streatham Campus

St Luke's Campus

Penryn Campus

Truro Campus

• Using our site
• Accessibility
• Freedom of Information
• Modern Slavery Act Statement
• Data Protection
• Copyright & disclaimer
• Cookie settings

UK CENTRE FOR MEDICAL RESEARCH AND INNOVATION

India must embrace a hybrid model that aligns research with industry needs, and avoid the US path

Narendra Modi launched the Anusandhan National Research Foundation with a ₹50k crore budget over five years to align academic research with industry needs. The initiative aims to avoid inefficiencies seen in the US system and leverage India's strengths in practical applications, exemplified by IIT Madras's successful industry-academic collaborations.

Unveiling an era of promise and possibilities: Abu Dhabi’s blueprint for propelling AI-led innovations in healthcare

In conversation with Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Center, Department of Health (DoH), who shares critical insights into the Abu Dhabi Global Health Week key agendas, including advancing neurodegenerative disease patient care, public-private partnerships to develop a robust and resilient healthcare sector worldwide, nurturing Gen AI-based healthtech startups in Abu Dhabi, and fostering innovations in biotech and life sciences.

US animal health major Zoetis expands GCC in Hyderabad

Zoetis, the world's largest producer of pet and livestock medicine, is expanding its global capability centre in Hyderabad. The centre will add around 300 technology jobs by next year and support the company's global operations using advanced technology tools. This expansion aims to leverage Hyderabad's tech talent pool and life-science ecosystem.

Eyestem completes first set of patient injections for Dry AMD treatment

Eyestem Research has completed the first set of patient injections for its RPE suspension therapy aimed at treating Dry age-related macular degeneration (AMD).

Tax terrorism? A storm brewing in India’s academic circles can't be taken for granted

Seven top Indian institutions, including IIT Delhi and Anna University, have received showcause notices from the Directorate General of GST Intelligence for unpaid taxes on research grants since 2017. This has sparked a debate within the academic community, with some calling it 'tax terrorism.' Legal experts urge the Centre to reconsider before the matter reaches courts.

SFAL-backed startups breaking barriers, creating cutting-edge products, says IT/BT Minister Priyank Kharge

Morphing Machines, an SFAL-supported fabless semiconductor company, has developed Redefine, which would cater to emerging workloads in areas such as telecom, AI/ML, healthcare, and high-performance computing. The startup has secured $2.76 million (Rs 23 crore) in a seed funding round led by Speciale Invest, the minister said.

TB testing technology developed by ICMR's regional centre allows tests at Rs 35

ICMR has introduced a new CRISPR-based technology for detecting tuberculosis at a low cost. Capable of testing 1,500 samples in a short period, this system aims to address limitations of existing methods. ICMR plans to commercialise this technology, offering technical support and seeking partner organisations.

Kolkata doctor murder-rape case: UK, Germany, Bangladesh and other countries hold protest to show solidarity

Global protests unfolded in response to the RG Kar rape-murder case. Demonstrations were seen across Times Square, Cologne, Manchester, and Dhaka University, among other locations. Communities, including expatriate Bengalis and local supporters, united to demand justice for the victim and call for systemic changes to protect women.

India eases drug approval process, waives local trials for advanced therapies

In a major policy shift, the Indian government has waived local clinical trial requirements for drugs and vaccines approved by major international regulators (US, UK, Japan, Australia, Canada, EU). This move, aimed at expediting access to advanced therapies like CAR T-cell therapy and Sacituzumab govitecan, still ensures post-marketing surveillance by the CDSCO.

Advancing global health: Innovations and collaborations for a healthier future

The ET Health Conclave on July 28, 2024, at Westin Gurgaon brought healthcare leaders together to discuss the future of healthcare. Key panels addressed topics such as robotics in medical practices, the role of AI, genomics, and HealthTech companies. The event provided a platform for innovations and collaborations in the health sector.

ETtech in-depth: Is India still playing catch-up with China and the US in quantum computing?

India launched the National Quantum Mission with a budget of over Rs 6,003 crore last year. In 2023, China reportedly invested $15 billion, however, India is determined to take that quantum leap and nothing exemplifies that better than Tata Institute of Fundamental Research (TIFR), Defense Research and Development Organisation (DRDO) and Tata Consultancy Services (TCS) building India’s largest quantum computer.

Budget 2024: Healthcare sector experts urge govt to boost spending, infrastructure and innovation

Experts in the healthcare sector are advocating for increased government spending, improved infrastructure, and enhanced innovation to strengthen India's healthcare system before the budget. They stress the importance of addressing health threats, achieving universal coverage, and professionalizing public health institutes. Recommendations include restructuring schemes, boosting domestic manufacturing, and increasing healthcare spending to 2.5% of GDP to enhance accessibility and affordability.

Budget FY25: Pharmaceuticals sector needs a major boost with increased focus on R&D and innovation

The Union Budget 2024-2025, pivotal for India's Amrit Kaal vision, aims to foster economic growth and inclusive development. The budget is expected to boost infrastructure, streamline bureaucracy, and promote technology and innovation. Emphasis on the pharmaceutical sector, with increased allocations, can drive India's economic and healthcare advancements.

SaaS startup AiDash unveils new AI centre of excellence in Bengaluru

This facility is set to become a hub of innovation and advanced research, dedicated to driving significant advancements in artificial intelligence (AI), remote sensing, and geospatial analytics.

Alpha generators in the long term: 9 mid and small cap stocks from pharma and healthcare sector with an upside potential of up to 29%

While some make it to the headlines, some don't. Two sectors, healthcare and pharma have been witnessing more mergers and acquisitions than any other sector. There is a logical reason why private equity money is flowing in these sectors. Probably these two sectors are the ones with maximum potential to grow over the next decade or so. In the case of pharma, facts are well known, right from skilled manpower to lower manufacturing costs. In the case of healthcare, there are two things: first, medical tourism, second, soft exports of medical services. Not many may know, some of the best known doctors from India fly to CIS and other countries, where the healthcare companies have their OPD. Either the patient is treated there, if possible or else he is referred to India for treatment. While it might sound impossible, given the broken healthcare system which even some of the best developed countries have, in future, Indian healthcare companies taking over global hospitals may also become a reality.

India can be third pillar of growth with US, UK: TCS CEO K Krithivasan

Tata Consultancy Services CEO emphasizes the importance of emerging markets like India for future growth. Discusses revenue trends, technology spends post-US elections, and interest rate cuts. Highlights deepening engagement with Tata Group firms and employee work from office policies.

Medtronic to invest $60 million on global IT centre in Hyderabad

Medtronic announces a $60 million investment to expand its GIT Centre in Hyderabad, creating 300 new jobs. The centre will focus on cloud engineering, data platforms, digital health applications, automation, AI, and machine learning. Medtronic aims to boost productivity and drive growth in healthcare technology.

Budget 2024: Is a Rs 10 lakh insurance the vitamin India's healthcare system needs?

The Centre is considering doubling the beneficiary base of the Ayushman Bharat health insurance scheme over the next three years, starting with those aged above 70, alongside raising annual coverage to Rs 10 lakh. These proposals are anticipated in the upcoming Union Budget. The interim Budget increased Ayushman Bharat's allocation to Rs 7,200 crore for secondary and tertiary care, with Rs 646 crore for health infrastructure.

View: Some suggestions for systemic improvements to minimise, or stop, future NEET-NET-type leaks

Recent events have put the National Testing Agency (NTA) under scrutiny due to the leakage of the NEET-UG test paper, impacting admission to medical colleges. With over 2 million students taking the NEET exam annually for around 1 lakh competitive seats, the stakes are high for career-defining opportunities.

Karnataka contributes 22% to global R&D, says IT Minister Priyank Kharge

Karnataka IT Minister Priyank Kharge on Wednesday said the state is at the forefront of innovation, contributing 22 per cent to global R&D, and is leading in areas such as technology services. The state government is striving to make not just Karnataka but India a skilled nation, research and manufacturing destination, innovation capital and biotech and startup hub, he said.

Japanese meditech Olympus Corporation to establish R&D and offshore development centre in Hyderabad

Olympus currently has R&D centers in Japan, US and Europe and is planning to leverage Indian local talent and resources to drive advancement in Indian medical technology. The decision follows a strategic agreement with HCL Tech, aimed at expanding Olympus' innovation generation activities globally. Olmpus makes medical devices such as endoscopy, imaging systems, surgical instruments.

Chinese scientists develop cure for diabetes, insulin patient becomes medicine-free in just 3 months

Chinese scientists achieve diabetes cure through innovative cell therapy, detailed in Cell Discovery. Patient, treated in July 2021, no longer requires insulin after eleven weeks, and is now medication-free for 33 months. The breakthrough, praised by Timothy Kieffer, signifies a major advancement in diabetes treatment. This novel approach utilizes the body's regenerative abilities and could alleviate China's healthcare burden. Further studies are needed for validation.

World Hypertension Day: Identifying risks, monitoring high BP, and adopting preventive measures to address this silent killer

To address the ticking bomb called hypertension, commonly referred to as high blood pressure, The Economic Times, in collaboration with USV, brings a special World Hypertension Day episode titled ‘The Brain, The Heart, and The Kidney: The Trifecta of Hypertension’, featuring a panel of esteemed experts, Dr. Ajit Mehta, Dr Soumik Chaudhuri, and Dr. Basavaraj G S. This significant discussion aimed to address the critical connection between hypertension and our vital organs. Here are the highlights.

Responsible Innovation, how a blueprint for collaborative action is advancing global healthcare

On the occasion of the Abu Dhabi Global Healthcare Week (ADGHW), Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre, discusses the UAE's prioritisation of healthcare in driving investments and partnerships focusing on advancing technology and attracting top talent and fostering collaboration with India reflecting shared challenges and opportunities in healthcare. Overall, collaboration with global partners and investment in manufacturing capabilities exemplify the UAE's commitment to healthcare excellence and innovation, while initiatives like Malaffi enhance data-driven services. Read on to discover how ADGHW aims to faciliate responsible innovation in healthcare, even as the UAE emphasises patient rights protection in an era of advancing AI and data usage.

Empowering healthcare innovations: Dr. Noura Khamis Al Ghaithi on ADGHW's role in global healthcare collaboration

H.E. Dr. Noura Khamis Al Ghaithi discusses ADGHW as a platform for global healthcare collaboration, focusing on innovations and partnerships with Indian healthcare providers. The event aims to develop precision health initiatives, strengthen life sciences research, attract medical tourism, and support a growing startup ecosystem.

GPU access to power up India’s AI play: experts

AI Mission will help startups make in India and for the world, say tech investors. The Rs 10,372-crore Artificial Intelligence (AI) Mission, announced on Thursday, will operate on a public-private partnership model.

Medtronic opens its expanded innovation centre in Hyderabad

Medtronic has expanded its Medtronic Engineering and Innovation Center (MEIC) in Hyderabad, India. The state-of-the-art R&D center, part of Medtronic's $350 million investment plan over five years, aims to expand its global R&D footprint and foster local innovation. The center focuses on collaborative innovation, training, and immersive experiences, housing labs like Digital Therapy & Innovation, Connected Care, and Platform & Tech

Innovation and Research: The Vital Work of Healthcare Management Scientists

Healthcare management scientists are professionals in the medical and research fields who focus on expanding their understanding of the health sector through research. They work on various research projects, including data collection, disease study, genetic predisposition analysis, and the development of new medical equipment. After completing health science coursework, individuals can pursue careers as home health aides, surgical technologists, human service assistants, radiologic specialists, or community health specialists. Healthcare scientists can work in hospitals, clinics, pharmaceutical companies, government agencies, consulting firms, and insurance companies. The salary for healthcare scientists varies based on experience and job category.

Centre to set up micro-seismic observation systems at Joshimath: Jitendra Singh

Addressing the workshop, he said there was a critical need for fundamental research on the physical processes that lead to failure of the brittle layers beneath the crust and sub-crust. The minister noted that human consequences of natural disasters in India were rising rapidly and stressed on the need to devise proper mitigation strategies.

UK Research and Innovation

We invest in research and innovation to enrich lives, drive economic growth, and create jobs and high-quality public services across the UK. We are transforming tomorrow together.

This is the website for UKRI: our seven research councils, Research England and Innovate UK. Let us know if you have feedback or would like to help improve our online products and services .

UKRI annual report 2023 to 2024

'Lab in a suitcase' could provide safer water for millions

The impact of design: symptoms, systems and stories

Pinned article from 16 September 2024

Update on UKRI’s journey to open access

17 September 2024

Sign up for free family science weekend in Cardiff next month

16 September 2024

New therapy that destroys tau tangles shows promise for Alzheimer’s

13 September 2024

New insight into links between menopause timing and cancer risk

12 September 2024

Finalists for prestigious Celebrating Impact Prize 2024 announced

View all news

Subscribe to UKRI emails

Keep up to date with funding, news and events, and a weekly newsletter.

World Class Labs for world class arts and humanities

10 September 2024

Tackling geohazards in India through international collaboration

View all blog posts

We invest £8 billion of taxpayers’ money each year into research and innovation and the people who make it happen. We work across a huge range of fields – from biodiversity conservation to quantum computing, and from space telescopes to innovative health care. We give everyone the opportunity to contribute and to benefit, bringing together people and organisations nationally and globally to create, develop and deploy new ideas and technologies.

Read our first five-year strategy